Fig. 4From: Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experienceSymptoms of depression, anxiety and pain catastrophizing scores at baseline (T0), and at the end of the third (T1) and sixth month (T2) of galcanezumab administrationsBack to article page